Fatty Liver Disease - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Fatty Liver Disease - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 123-page report is available in PDF from $2000.

Fatty Liver Disease - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Fatty Liver Disease - Pipeline Review, H1 2015’, provides an overview of the Fatty Liver Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Fatty Liver Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Fatty Liver Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fatty Liver Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Fatty Liver Disease Overview 10
Therapeutics Development 11
Pipeline Products for Fatty Liver Disease - Overview 11
Pipeline Products for Fatty Liver Disease - Comparative Analysis 12
Fatty Liver Disease - Therapeutics under Development by Companies 13
Fatty Liver Disease - Therapeutics under Investigation by Universities/Institutes 16
Fatty Liver Disease - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Fatty Liver Disease - Products under Development by Companies 21
Fatty Liver Disease - Products under Investigation by Universities/Institutes 23
Fatty Liver Disease - Companies Involved in Therapeutics Development 24
ACROVIS biostructures GmbH 24
ChemoCentryx, Inc. 25
Conatus Pharmaceuticals Inc. 26
Daewoong Pharmaceutical Co., Ltd. 27
Dr. Falk Pharma GmbH 28
DURECT Corporation 29
Galmed International Ltd. 30
Generon (Shanghai) Corporation Ltd. 31
Genovate Biotechnology Co., LTD. 32
Gilead Sciences, Inc. 33
Huons Co., Ltd. 34
Kyorin Pharmaceutical Co., Ltd. 35
Metabolic Solutions Development Company, LLC 36
Novartis AG 37
Protalix BioTherapeutics, Inc. 38
Raptor Pharmaceuticals Corp. 39
TCM Biotech International Corp 40
Tobira Therapeutics, Inc. 41
Verva Pharmaceuticals Limited 42
Zafgen Inc. 43
Fatty Liver Disease - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Target 45
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 51
Drug Profiles 53
ACR-488 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Aramchol - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CCX-872 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
cenicriviroc mesylate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CSN-501 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
cysteamine DR - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
DV-928 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DWP-10292 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
emricasan - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
etanercept biosimilar - Drug Profile 68
Product Description…

For more information open Fatty Liver Disease - Pipeline Review, H1 2015.


Original Article: Fatty Liver Disease - Pipeline Review, H1 2015


More From BioPortfolio on "Fatty Liver Disease - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...